SEC EDGARAUG 201 min read$CRL

Andrews Nancy C sold $163K of CRL

Andrews Nancy C sold 573 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $285.24 ($0.16M total) on 2026-08-18.

Original reporting

SEC EDGAR · Andrews Nancy C

Published Aug 20, 2026, 8:31 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CRL

Neutral

high confidence

Mentioned

$CRL

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CRLNeutralLow

Why it matters

The disclosed sale is a routine insider transaction with limited market impact.

Market read

Low relevance; the filing is a standard Form 4 disclosure with modest financial magnitude.

What to watch

Potential upcoming earnings or regulatory updates that may influence insider behavior.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-20

Background

Charles River Laboratories is a contract research organization providing services to the pharmaceutical and biotech industries.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CRLNeutralHigh confidence

Context

Director Nancy Andrews sold 573 shares of Charles River Laboratories for $163,442, reducing her holding to 1,438 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size is small relative to market cap and typical insider activity, and no broader catalyst is indicated.

Market effects

Sector

None; the sale does not affect the broader healthcare services sector.

Regional

None; limited to a single insider transaction.

Global

None; no global implications.

Counterpoint

What could challenge this read

If the director is reducing exposure due to anticipated negative news, the sale could foreshadow a downside.

Key entities

Director
Nancy Andrews
Director of Charles River Laboratories who sold shares.

Read at source ← All news

SEP 17

$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.

financialcontent.com2 min

SEP 15

$CRLMed

Charles River Laboratories at 2026 Global Healthcare Conference: growth builds

Charles River Laboratories (CRL) reported growth at the 2026 Global Healthcare Conference, with CEO Birgit Statham and CFO Glenn Sblendorio highlighting momentum in key segments. The company raised full-year organic growth and EPS guidance, citing stronger bookings in Discovery and Safety Assessment and improving margins in Manufacturing Support. Management also noted progress in stabilizing the non-human primate supply chain. However, they cautioned that recent strength may not sustain at the c

investing.com3 min

SEP 1

$CRLMedAI 8/10

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River Laboratories (CRL) is well-positioned for growth due to strong research-model demand and portfolio streamlining. The company's DSA segment shows improving demand, bookings, and backlog. CRL stock has surged 79% over the past year, outperforming its industry and the S&P 500. The company has a market cap of $13.92 billion and an earnings yield of 3.9%. However, mixed demand trends and NHP-related cost volatility remain risks. The Zacks Consensus Estimate for CRL’s 2026 earnings has i

tradingview.com3 min

AUG 31

$IQVMedAI 8/10

Q2 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment

Azenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.

finance.yahoo.com3 min

AUG 21

$ACBHighAI 8/10

Aurora Snipes Back At Curaleaf’s Hostile Bid

Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.

yahoo.com2 min

AUG 19

$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min